WATERTOWN, Mass. - Officials at VI Technologies have begun Phase II clinical trails with their INACTINE pathogen reduction red blood cell system - the same system that reportedly can inactive Lyme Disease and West Nile pathogens.
"West Nile virus and the bacterium that causes Lyme disease are prime examples of emerging pathogens," says company president and CEO John R. Barr." Further epidemiologic studies in human transfusion recipients are needed before the transfusion risk, if any, can be ascertained. The results of these studies strengthen the power of the technology - which inactivates an unmatched list of enveloped and non-enveloped viruses, gram negative and gram positive bacteria, parasites and lymphocytes."
Additional information is available at www.vitechnologies.com.